DeepMed Research

APELLIS PHARMACEUTICALS, INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2008-01-01

Employees: 706

Market Cap: $4.8B

Website: http://www.apellis.com

Clinical Trials

Geographic Atrophy Long-Terms Outcomes Study

Completed

Conditions: Geographic Atrophy

First Posted Date: 2024-07-12

Last Posted Date: 2024-07-12

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 255

Registration Number: NCT06499571

Locations: 🇫🇷
Centre Hospitalier de la Croix Rousse, Lyon Cedex 04, Rhone, France
🇦🇺
Sydney West Retina, Westmead, New South Wales, Australia
🇮🇹
Azienda Socio Sanitaria Territoriale Fatebenefratelli (Presidio Ospedale Sacco), Milano, Italy

and more 2 locations

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Recruiting

Conditions: Geographic Atrophy

Interventions: Drug: Pegcetacoplan

First Posted Date: 2023-12-08

Last Posted Date: 2025-02-25

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 300

Registration Number: NCT06161584

Locations: 🇺🇸
Illinois Retina Associates (01-037), Oak Park, Illinois, United States
🇺🇸
California Retina Consultants (01-026), Bakersfield, California, United States
🇺🇸
Retina-Vitreous Associates Medical Group (01-020), Beverly Hills, California, United States

and more 30 locations

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Phase 3

Active, not recruiting

Conditions: C3 Glomerulopathy
DDD
Membranoproliferative Glomerulonephritis
Complement 3 Glomerulopathy
Membranoproliferative Glomerulonephritis (MPGN)
IC-MPGN
C3 Glomerulonephritis
Complement 3 Glomerulonephritis
Dense Deposit Disease
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Interventions: Drug: Pegcetacoplan

First Posted Date: 2023-04-12

Last Posted Date: 2025-03-28

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 100

Registration Number: NCT05809531

Locations: 🇺🇸
Academic Medical Research Institute (01034), Los Angeles, California, United States
🇺🇸
Children's Hospital Colorado (01037), Aurora, Colorado, United States
🇺🇸
University of Florida, Department of Pediatric Nephrology (01010), Gainesville, Florida, United States

and more 44 locations

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Phase 3

Completed

Conditions: C3G
Membranoproliferative Glomerulonephritis (MPGN)
IC-MPGN
Complement 3 Glomerulopathy
Complement 3 Glomerulonephritis
Dense Deposit Disease
DDD
C3 Glomerulopathy
Complement 3 Glomerulopathy (C3G)
C3 Glomerulonephritis

Interventions: Other: Placebo
Drug: Pegcetacoplan

First Posted Date: 2021-10-05

Last Posted Date: 2025-03-13

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 124

Registration Number: NCT05067127

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
🇳🇱
Emma Kinderziekenhuis, Amsterdam UMC, Amsterdam, Netherlands
🇳🇱
Radboud University Medical Center, Nijmegen, Netherlands

and more 120 locations

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2

Recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal Hemoglobinuria

Interventions: Drug: Pegcetacoplan

First Posted Date: 2021-05-26

Last Posted Date: 2022-07-20

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 12

Registration Number: NCT04901936

Locations: 🇹🇭
Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand
🇨🇿
Motol University Hospital, Prague, Czechia
🇺🇸
Children's Hospital of Atlanta, Atlanta, Georgia, United States

and more 7 locations

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

Phase 3

Active, not recruiting

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions: Drug: PEGCETACOPLAN (APL-2)

First Posted Date: 2021-02-25

Last Posted Date: 2025-03-06

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 1200

Registration Number: NCT04770545

Locations: 🇺🇸
Northwestern Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States

and more 164 locations

C3G/Primary IC-MPGN EAP

Conditions: C3G
IC-MPGN
C3 Glomerulopathy
C3 Glomerulonephritis
Complement 3 Glomerulopathy
Complement 3 Glomerulopathy (C3G)
Complement 3 Glomerulonephritis
Dense Deposit Disease
DDD
Membranoproliferative Glomerulonephritis

First Posted Date: 2021-01-28

Last Posted Date: 2024-07-26

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Registration Number: NCT04729062

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Terminated

Conditions: Amyotrophic Lateral Sclerosis
Motor Neuron Disease

Interventions: Drug: Pegcetacoplan (APL-2)
Other: Placebo

First Posted Date: 2020-10-08

Last Posted Date: 2025-04-24

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 249

Registration Number: NCT04579666

Locations: 🇦🇺
Brain and Mind Centre, Camperdown, New South Wales, Australia
🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Hospital for Special Surgery, New York, New York, United States

and more 57 locations

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Phase 2

Active, not recruiting

Conditions: Renal Transplant
Dense Deposit Disease (DDD)
Membranoproliferative Glomerulonephritis (MPGN)
Complement 3 Glomerulonephritis
Membranoproliferative Glomerulonephritis
C3 Glomerulonephritis
C3G
Complement 3 Glomerulopathy
Complement 3 Glomerulopathy (C3G)
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Interventions: Drug: Pegcetacoplan

First Posted Date: 2020-10-01

Last Posted Date: 2025-03-30

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 13

Registration Number: NCT04572854

Locations: 🇮🇹
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica, Italy
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States

and more 22 locations

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

Phase 1

Completed

Conditions: Covid-19
Ards
Coronavirus
Coronavirus Infection
Severe Acute Respiratory Syndrome
Severe Acute Respiratory Syndrome Coronavirus 2
Sars-CoV2
COVID
Acute Respiratory Distress Syndrome

Interventions: Other: Vehicle Control
Drug: APL-9

First Posted Date: 2020-05-26

Last Posted Date: 2022-03-23

Lead Sponsor: Apellis Pharmaceuticals, Inc.

Target Recruit Count: 72

Registration Number: NCT04402060

Locations: 🇺🇸
Rutgers University - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸
Westchester General Hospital, Miami, Florida, United States

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy